Today: July 21, 2017, 7:05 am
  
Health

Presbyopia - Pipeline Review, H1 2017 - New Report Available

Fast Market Research recommends "Presbyopia - Pipeline Review, H1 2017" from Global Markets Direct, now available
Presbyopia - Pipeline Review, H1 2017 - New Report Available
PR-Inside.com: 2017-07-17 15:58:22
Presbyopia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.


Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Full Report Details at
- www.fastmr.com/prod/1293679_presbyopia_pipeline_h1_2017.aspx?afi ..

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 1 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

* The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
* The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
* The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
* The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
* The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
* The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
* The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
* The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

Reasons to Get this Report

* Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
* Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
* Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
* Classify potential new clients or partners in the target demographic.
* Develop tactical initiatives by understanding the focus areas of leading companies.
* Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
* Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in this Report: Acucela Inc, Allergan Plc, Johnson & Johnson, Novartis AG

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033&afid=701

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information


Published by
Bill Thompson
18008448156
e-mail
www.fastmr.com



# 796 Words
Related Articles
More From The Author
Now Available: China Transurethral Resection of the [..]
China Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2023 Summary GlobalData's new report, "China Transurethral [..]
Institutional Construction Market in China: Market Size, [..]
Institutional construction market covers the development of government, public and religious buildings. This market includes five [..]
TrendSights Analysis: Moderation & Avoidance - New [..]
TrendSights Analysis: Moderation & Avoidance - Empowering consumers to limit or avoid specific ingredients, or products; by [..]
The Cards and Payments Industry in Croatia: [..]
The Cards and Payments Industry in Croatia: Emerging trends and opportunities to 2020 Summary GlobalData's "The Cards and [..]
Country Profile: Bakery & Cereals sector in [..]
Country Profile: Bakery & Cereals sector in Turkey Summary The Bakery & Cereals sector in Turkey is led by the [..]
 
More From Health
CLA Safflower Oil is Under Review, and [..]
The competition is mainly between two important brands, and it is about how much more effective safflower oil is compared [..]
Oyaco & Home HealthCare Shoppe are Coming [..]
Oyaco has always been a trustworthy name among the parents. The products that they sell are of the utmost quality [..]
Plasma Nutrition Launches World’s First Reduced-Calorie Protein [..]
People looking to lose weight or keep it under control can now add protein to their diet, reduce daily calories [..]
Eureka Dental Group in-house laboratory in West [..]
While in the chair, impressions can be made both physically and with computer modeling. These are then expertly transferred to [..]
Healthy Skin & Body is Possible Now [..]
New Delhi, Friday, June, 30, 2017: Floral Absolute Oils are always in demand as it is naturally extracted oil that [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.